Leeward Investments LLC MA Sells 3,017 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Leeward Investments LLC MA lowered its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 0.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 384,191 shares of the life sciences company’s stock after selling 3,017 shares during the quarter. Leeward Investments LLC MA’s holdings in Integra LifeSciences were worth $16,732,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Signaturefd LLC boosted its position in Integra LifeSciences by 248.5% during the fourth quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock worth $25,000 after purchasing an additional 415 shares during the period. Gladius Capital Management LP bought a new stake in Integra LifeSciences during the third quarter worth approximately $47,000. Covestor Ltd boosted its position in Integra LifeSciences by 82.5% during the third quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock worth $78,000 after purchasing an additional 921 shares during the period. International Assets Investment Management LLC bought a new stake in Integra LifeSciences during the fourth quarter worth approximately $190,000. Finally, Empirical Asset Management LLC bought a new stake in shares of Integra LifeSciences in the fourth quarter valued at approximately $212,000. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART opened at $28.34 on Friday. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94. The business has a fifty day simple moving average of $35.34 and a 200 day simple moving average of $38.76. Integra LifeSciences Holdings Co. has a one year low of $27.18 and a one year high of $56.21. The firm has a market capitalization of $2.23 billion, a price-to-earnings ratio of 34.14, a PEG ratio of 0.86 and a beta of 1.12.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.01). Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The company had revenue of $397.00 million for the quarter, compared to analyst estimates of $399.30 million. During the same quarter in the prior year, the company earned $0.94 earnings per share. The business’s revenue was down .3% compared to the same quarter last year. Sell-side analysts expect that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on IART shares. JMP Securities reduced their price objective on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research report on Thursday, February 29th. Truist Financial reduced their price objective on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research report on Friday, March 1st. StockNews.com cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Friday, April 5th. Finally, Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price objective for the company in a research report on Wednesday, April 3rd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $44.89.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.